...
首页> 外文期刊>Haematologica >Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation.
【24h】

Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation.

机译:同种异体造血干细胞移植后受体型内皮细胞的持续存在。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The possibility that allogeneic hematopoietic stem cell transplantation performed across the ABO blood group-barrier is associated with an increase of graft-versus-host disease, in particular endothelial damage, has not been elucidated so far. For this reason, we investigated the level of endothelial cell chimerism after allogeneic hematopoietic stem cell transplantation in order to delineate the role of hematopoietic stem cells in endothelial replacement. DESIGN AND METHODS: The frequency of donor-derived endothelial cells was analyzed in 52 hematopoietic stem cell transplant recipients, in 22 normal skin biopsies, in 12 skin samples affected by graft-versus-host disease, various tissues from five autopsies and four secondary solid tumors by ABH immunohistochemistry, XY fluorescence in situ hybridization and short tandem repeat analysis of laser captured endothelial cells. RESULTS: Skin biopsies from two patients transplanted with minor ABO-incompatible grafts (i.e. O in A) showed 3.3 and 0.9 H antigen-positive donor-derived endothelial cells by ABH immunohistochemistry. Tumor biopsies from two recipients showed 1.2 and 2.5 donor-derived endothelial cells by combined immunohistochemistry/ fluorescence in situ hybridization. All other skin samples, heart, liver, bone-marrow, and tumor tissues failed to reveal donor-type endothelial cells up to several years after ABO-incompatible hematopoietic stem cell transplantation. CONCLUSIONS: Endothelial cell replacement by bone marrow-derived donor cells after allogeneic hematopoietic stem cell transplantation is a rare event. It does not seem to represent a major mechanism of physiological in vivo blood vessel formation, tumor neoangiogenesis, vascular repair after graft-versus-host disease episodes or acceptance of ABO-incompatible grafts.
机译:背景:迄今为止,尚未阐明跨 ABO 血型屏障进行的同种异体造血干细胞移植与移植物抗宿主病(尤其是内皮损伤)增加有关的可能性。为此,我们研究了同种异体造血干细胞移植后内皮细胞嵌合的水平,以描述造血干细胞在内皮替代中的作用。设计和方法: 通过 ABH 免疫组织化学、XY 荧光原位杂交和激光捕获的内皮细胞的短串联重复分析,分析了 52 名造血干细胞移植受者、22 例正常皮肤活检、12 份受移植物抗宿主病影响的皮肤样本、5 例尸检和 4 例继发性实体瘤的各种组织。结果:通过 ABH 免疫组织化学,两名移植了轻微 ABO 不相容移植物(即 A 中的 O)的患者的皮肤活检显示 3.3% 和 0.9% H 抗原阳性供体来源的内皮细胞。通过免疫组化/荧光原位杂交,两名受者的肿瘤活检显示 1.2% 和 2.5% 的供体来源的内皮细胞。所有其他皮肤样本、心脏、肝脏、骨髓和肿瘤组织在ABO不相容的造血干细胞移植后数年内未能显示供体型内皮细胞。结论:同种异体造血干细胞移植后骨髓来源的供体细胞替代内皮细胞是罕见的事件。它似乎并不代表生理性体内血管形成、肿瘤新血管生成、移植物抗宿主病发作后的血管修复或接受 ABO 不相容移植物的主要机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号